PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Fluocinolone acetonide - Diabetic macular oedema

PAD Profile : Fluocinolone acetonide - Diabetic macular oedema Important

Keywords :
DMO, Retinal disorder
Brand Names Include :
Iluvien
Important Information :
Ophthalmology specialists only. In patients who have failed to respond to prior treatments.

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravitreal implant
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 May 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves fluocinolone acetonide intravitreal implant as a treatment option in line with the recommendations made in NICE TA953, for treating diabetic macular oedema.

 

Fluocinolone acetonide for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

 

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

02 November 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a Diabetic Macular Oedema (DMO) treatment pathway attached below for information. 

Associated BNF Codes

11. Eye
11.04.01. Corticosteroids
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More